17 results about "Valvular heart disease" patented technology

The invention discloses a heart valvular disease digital management system, which relates to the technical field of medical data management, and is characterized in that a data acquisition module comprises an automatic acquisition unit and a multi-channel input unit; the storage management module comprises a data storage unit and a data management unit; the monitoring and early warning module comprises a data analysis unit and a health early warning unit; the data visualization module comprises a chart display unit, a dynamic interaction unit and a report generation unit; the health assistant module comprises a personalized management unit, a follow-up visit management unit, a health activity evaluation unit, an intelligent reasoning unit and a family member unit. The system has an early risk perception and hospital-family linkage valvular heart disease full-process digital health management mode, can improve the active health management ability of patients, controls disease risk factors, effectively restrains the risk of cardiovascular diseases, and improves the overall quality and efficiency of medical services.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.

The invention discloses a valvular heart disease severity AI grading diagnosis method, which comprises the following steps of executing multi-source data acquisition, and acquiring a clinical medical record text, cardiac ultrasound image data and a valvular heart disease interventional therapy prognosis data set of a patient to be diagnosed; wherein the clinical medical record text comprises patient subjective symptom description information, and the interventional therapy prognosis data set comprises post-treatment symptom remission rate, complication occurrence rate and lifetime data of patients with different severity levels. The limitation that the prior art only depends on single objective image data is broken through; according to the method, symptom quantitative processing and targeted image feature extraction are combined, comprehensive capturing of multi-dimensional features is achieved, then a grading threshold value is reversely calibrated through a prognosis prediction result, grading deviation is effectively corrected, and the accuracy and clinical matching degree of grading diagnosis are remarkably improved.

The present invention provides, in part, a novel small molecule PHD inhibitor, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (A) and its sub-formula. Compounds provided herein are useful for the treatment of diseases, the diseases include heart diseases (e.g., ischemic heart disease, congestive heart failure and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease). # imgabs0 #

Part of this invention provides novel small molecule PHD inhibitors having structures according to formula (I) and its derivatives: or pharmaceutically acceptable salts thereof. The compounds provided herein may be used to treat the following diseases: including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory diseases (e.g., respiratory infections, acute respiratory distress syndrome), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease), inflammatory bowel disease (IBD), ischemic-reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present invention provides, in part, novel small molecule PHD inhibitors having a structure according to Formula (A) or its subformulas: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful for treating diseases including heart disease (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung disease (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver disease (e.g., acute liver failure and liver fibrosis and cirrhosis), and kidney disease (e.g., acute kidney injury and chronic kidney disease). #imgabs0#

Disclosed are compounds of formulas (I) and (II), a salt thereof, or an optical isomer thereof, wherein R1-R3, X, and Y are as defined herein, which are 5-HT2B serotonin receptor selective antagonists, pharmaceutical compositions comprising such compounds, and methods of treating various diseases and conditions in an animal including fibrosis of the lung, skin, coronary, and liver, pulmonary arterial hypertension, valvular heart disease, pain, and cancer by the use of these compounds.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof:or a pharmaceutically acceptable salt thereof.  The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI). 

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.

The present invention relates to the field of standardized identification technology, and more specifically, to a method and system for cardiovascular disease identification based on medical insurance data. The scheme includes obtaining a medical insurance database, storing the information as a medical insurance data group according to the time of information entry; setting a standard name dictionary including heart failure, heart failure, ischemic heart disease or coronary heart disease, valvular heart disease, arrhythmia, thrombotic disease, peripheral vascular disease, cerebrovascular disease, pulmonary vascular disease, hypertension and aortic aneurysm according to the relevant disease diagnosis names; performing keyword matching, similarity analysis and matching according to the standard name dictionary and the medical insurance data group, and forming a standard classification list with the third standard dictionary; storing and displaying according to the standard classification list. After obtaining the medical insurance data, the scheme performs a three-level similarity analysis according to the standard diagnosis name, completes multiple diagnostic dictionary updates, and forms a standardized identification method that is highly efficient and suitable for practical applications.

The present invention provides, in part, novel small molecule PHD inhibitors or pharmaceutically acceptable salts thereof, the inhibitors having a structure according to formula (A) and its subformulae. The compounds provided herein can be used to treat diseases including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease).

Aortic valve stenosis (AS), is the most frequent valvular heart disease in Europe and affects more than 1 in 4 people over 65 years old. AS progression from fibrotic thickening to valvular leaflets calcification leads to heart failure development and eventually to death within 2 to 5 years after symptoms occurrence. The inventors now show that endothelin receptor type B (ETB) activation with an agonist decreased the calcium content of VIC. Therefore, the present invention relates to the use of endothelin receptor type B (ETB) agonists for the treatment of aortic valve stenosis.

The invention provides application of melatonin and / or a melatonin receptor stimulant and / or a Gas6 protein inhibitor and / or an AXL receptor tyrosine kinase inhibitor in prevention and / or treatment of valvular heart disease. Specifically, the invention provides application of a first component and an optional second component in preparation of a medicine for preventing and / or treating diseases caused by heart valve mucus-like degeneration, the first component comprises melatonin and / or a melatonin receptor agonist, and the second component comprises an AXL receptor tyrosine kinase inhibitor and / or a Gas6 protein inhibitor. The invention lays a foundation for research on heart valve mucus-like degeneration and diseases caused by the heart valve mucus-like degeneration, and has important clinical application and scientific research values.

The present invention provides in part novel small molecule PHD inhibitors having a structure according to formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be used to treat diseases including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease).